PRODUCT INFORMATION

GZD-824

Item No. 21508

CAS Registry No.:	1257628-77-5
Formal Name:	4-methyl-N-[4-[(4-methyl-1-piperazinyl) methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]-benzamide
MF:	$C_{29}H_{27}F_3N_6O$
FW:	532.6
Purity:	≥98%
UV/Vis.:	λ_{max}: 274, 324 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GZD-824 is supplied as a crystalline solid. A stock solution may be made by dissolving the GZD-824 in the solvent of choice. GZD-824 is soluble in the organic solvent DMSO, which should be purged with an inert gas.

Description

GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC_{50}s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/Abl^{T315I}, respectively).[1] It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells (IC_{50}s = 0.2 and 0.13 nM, respectively) and induce tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl.[1]

Reference

1. Ren, X., Pan, X., Zhang, Z., *et al.* Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. *J. Med. Chem.* **56(3)**, 879-894 (2013).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM